Aldosterone and Residual Cardiorenal Risk: Pathophysiology and Emerging Therapeutic Strategies.
This review distinguishes aldosterone excess from MR activation and proposes a nephrology-focused clinical framework separating established MRA indications, evaluation for primary aldosteronism, and the unestablished cardiorenal outcome role of aldosterone synthase inhibitors (ASIs).